ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results for Q4 2026 on Thursday, November 12th. The company reported earnings of -$3.04 per share, missing estimates of -$1.62 by $1.42. The company also reported revenue of $37,790,000, missing estimates of $56,955,076 by $-19,165,076.
You can see Quiver Quantitative's $ARWR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARROWHEAD PHARMACEUTICALS Insider Trading Activity
ARROWHEAD PHARMACEUTICALS insiders have traded $ARWR stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- MICHAEL S PERRY sold 11,600 shares for an estimated $1,012,680
- ADEOYE Y OLUKOTUN sold 2,000 shares for an estimated $173,920
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
ARROWHEAD PHARMACEUTICALS Hedge Fund Activity
We have seen 242 institutional investors add shares of ARROWHEAD PHARMACEUTICALS stock to their portfolio, and 262 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 3,330,966 shares (-18.3%) from their portfolio in Q2 2026, for an estimated $271,507,038
- NORGES BANK added 2,192,072 shares (+128.6%) to their portfolio in Q2 2026, for an estimated $178,675,788
- FMR LLC added 1,315,943 shares (+16.4%) to their portfolio in Q3 2026, for an estimated $86,128,469
- HOLOCENE ADVISORS, LP added 1,106,177 shares (+inf%) to their portfolio in Q2 2026, for an estimated $90,164,487
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 923,927 shares (+inf%) to their portfolio in Q2 2026, for an estimated $75,309,289
- FIRST TRUST ADVISORS LP removed 911,592 shares (-67.4%) from their portfolio in Q3 2026, for an estimated $59,663,696
- VESTAL POINT CAPITAL, LP removed 700,000 shares (-30.8%) from their portfolio in Q2 2026, for an estimated $57,057,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
ARROWHEAD PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 3 analysts offer price targets for $ARWR in the last 6 months, with a median target of $90.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 07/01/2026
- Keay Nakae from Chardan Capital set a target price of $90.0 on 06/30/2026
- Mani Foroohar from Leerink Partners set a target price of $72.0 on 06/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
